News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bristol-Myers Squibb Company (BMY) Immune Drug Shows Promise in Three Cancers, Success May Spur Industry Race


6/4/2012 6:57:47 AM

The early success of an experimental drug from Bristol-Myers Squibb Co. that’s designed to unleash the body’s immune-system defenses against cancer sets the stage for an industry wide race to produce similar treatments. The drug shrank tumors in people with advanced lung, kidney and skin cancer in 18 percent to 28 percent of patients, depending on the illness, who had failed on other therapies, according to data from a 296-patient trial reported June 2 at the American Society of Clinical Oncology meeting in Chicago.

Read at BusinessWeek
Read at RTT News
Read at Reuters
Read at Wall Street Journal

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES